Johnson & Johnson (J&J) has entered into a definitive agreement to acquire Firefly Bio for $1bn in cash, a move aimed at expanding its oncology research portfolio through the addition of Firefly Bio’s proprietary Firelink degrader-antibody conjugate (DAC) technology. The Firefly Bio acquisition is focused on advancing new treatment approaches for solid tumours associated with KRAS mutations, an area that continues to present significant challenges for cancer drug development. The transaction is expected to be completed later this year, subject to regulatory approvals and customary closing requirements.
At the centre of the deal is Firefly Bio’s preclinical-stage Firelink DAC platform, which has been developed to address limitations seen in existing therapies targeting Kirsten rat sarcoma viral oncogene homologue (KRAS)-driven cancers. According to the companies, the technology is designed to improve the delivery of protein degraders directly to tumour cells while reducing exposure to healthy tissue. Through the Firefly Bio Acquisition, J&J expects to broaden its pipeline with new preclinical candidates that could be applied across multiple solid tumour indications.
Commenting on the transaction, J&J innovative medicine research and development division executive vice-president John Reed said: “KRAS has notoriously been considered an undruggable target and patients with KRAS-driven cancers continue to face limited treatment options with survival measured in months, not years.
“We believe the proprietary Firelink platform will overcome the limitations of current treatments and diversify our pipeline with preclinical candidates for treating multiple types of solid tumours.”
Firefly Bio has concentrated its efforts on developing the Firelink DAC platform for cancer indications where therapeutic options remain limited. J&J noted that its more than three decades of oncology-focused innovation, combined with its existing antibody-engineering expertise, could be strengthened through the integration of Firefly Bio’s technology. The companies did not disclose details regarding future regulatory submissions or commercial launch timelines.
